Bis-benzylidine piperidone proteasome inhibitor with anticancer activity

Patent metadata

Field	Value
Publication number	US-9913834-B2
Application number	US-201414889768-A
Country	US
Kind code	B2
Filing date	May 6, 2014
Priority date	May 8, 2013
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190.

First claim

What is claimed is:

1. A compound having the structure of formula I,

wherein each pair of As is one of:
(i) phenyl, optionally substituted with 1-5 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q R1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ;
(ii) naphthyl, optionally substituted with 1-5 substituents selected from the consisting of R1, OR1, NR1R2, S(O) q R1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ;
(iii) a 5 or 6 membered monocyclic heteroaryl group, having 1-3 heteroatoms selected from the group consisting of O, N, and S, optionally substituted with 1-3 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q R1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ; and
(iv) an 8 to 10 membered bicyclic heteroaryl group containing 1-3 heteroatoms selected from the group consisting of O, N, and S; and the second ring is fused to the first ring using 3 to 4 carbon atoms, and the bicyclic hetero aryl group is optionally substituted with 1-3 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q R1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2;
wherein X is NP, wherein P is selected from the group consisting of R1, C(O)R1, C(O)OR1, C(O)NR1R2, S—N(R1)COOR1, and S—N(R1),
wherein Y is O
wherein R1 and R2 are selected from the group consisting of hydrogen, nitro, hydroxyl, carboxy, amino, halogen, cyano and C 1 -C 14 linear or branched alkyl groups, that are optionally substituted with 1-3 substituents selected from the group consisting of C 1 -C 14 linear or branched alkyl, up to perhalo substituted C 1 -C 14 linear or branched alkyl, C 1 -C 14 alkoxy, hydrogen, nitro, hydroxyl, carboxy, amino, C 1 -C 14 alkylamino, C 1 -C 14 dialkylamino, halogen, and cyano; and
wherein Z is selected from the group consisting of hydrogen; C 1 to C 14 linear, branched, or cyclic alkyls; phenyl; benzyl, 1-5 substituted benzyl, C 1 to C 3 alkyl-phenyl, wherein the alkyl moiety is optionally substituted with halogen up to perhalo; up to perhalo substituted C 1 to C 14 linear or branched alkyls; —(CH 2 ) q —K, where K is a 5 or 6 membered monocyclic heterocyclic ring, containing 1 to 4 atoms selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic, or an 8 to 10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said alkyl moiety is optionally substituted with halogen up to perhalo; and
wherein the variable q is an integer ranging from 0 to 4.

2. A compound having the following structure:

3. A compound having the following structure:

4. A compound having the following structure:

5. A method of treating a condition or a disease in a mammal by administering to the mammal a therapeutically effective dose of the compound of claim 1 wherein the condition is multiple myeloma.

6. The method of claim 5 wherein the mammal is a human.

7. A composition comprising the compound of claim 1 .

Assignees

• Univ Johns Hopkins

Inventors

• Roden Richard B
• Anchoori Ravi K
• Karanam Balasubramanyam

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/45 Primary

  having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide · CPC title

• C07D213/68

  attached in position 4 · CPC title

• A61K31/439

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title